Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inhibitor-induced dimerization mediates lufotrelvir resistance in mutants of SARS-CoV-2 3C-like protease.

Protein science : a publication of the Protein Society - 1 Sept 2025

Wang Guanyu, Venegas Felipe, Rueda Andres, Yañez Osvaldo, Osorio Manuel I, Qin Sibei, Pérez-Donoso José Manuel, Thibodeaux Christopher J, Moitessier Nicolas, Mittermaier Anthony K

Abstract excerpt

The emergence of SARS-CoV-2 and other lethal coronaviruses has prompted extensive research into targeted antiviral treatments, particularly focusing on the viral 3C-like protease (3CLpro) due to its essential role for viral replication. However, the rise of drug resistance mutations poses threats to public health and underscores the need to predict resistance mutations and understand the mechanism of how these...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Coronavirus 3C Proteases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Viral

Share to Mutation

Share to Protein Multimerization

Share to SARS-CoV-2

Source

Open in PubMed Open full text

Identifiers

PMID: 40852870
DOI: 10.1002/pro.70275
PMCID: PMC12375981

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inhibitor-induced dimerization mediates lufotrelvir resistance in mutants of SARS-CoV-2 3C-like protease.PMID 40852870Read ↗

Resistance mechanisms of SARS-CoV-2 3CLpro to the non-covalent inhibitor WU-04Semantic proximity Read ↗

A naturally occurring G11S mutation in the 3C-like protease from the SARS-CoV-2 virus dramatically weakens the dimer interface.Semantic proximity Read ↗

Resistance mechanisms of SARS-CoV-2 3CLpro to the non-covalent inhibitor WU-04Semantic proximity Read ↗

Development of small molecule non-covalent coronavirus 3CL protease inhibitors from DNA-encoded chemical library screeningSemantic proximity Read ↗

The substitutions L50F, E166A and L167F in SARS-CoV-2 3CLpro are selected by a protease inhibitor <i>in vitro</i> and confer resistance to nirmatrelvirSemantic proximity Read ↗

SARS-CoV-2 3CLpro mutations T21I and E166A confer differential resistance to simnotrelvir, bofutrelvir, and ensitrelvir.Semantic proximity Read ↗

Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitorsSemantic proximity Read ↗

Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitorsSemantic proximity Read ↗

Molecular mechanisms of drug resistance and compensation in SARS-CoV-2 main protease: the interplay between E166 and L50.Semantic proximity Read ↗

Predicting Antiviral Resistance Mutations in SARS-CoV-2 Main Protease with Computational and Experimental Screening.Semantic proximity Read ↗

Cross-resistance patterns in SARS-CoV-2 against 3CL protease inhibitors.Semantic proximity Read ↗

Contributions of hyperactive mutations in M <sup>pro</sup> from SARS-CoV-2 to drug resistanceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.